Latest Information Update: 21 Dec 2016
At a glance
- Originator Unknown
- Developer Karo Bio
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 03 Sep 1998 No-Development-Reported for Arrhythmias in Sweden (Unknown route)
- 15 Apr 1996 Preclinical development for Arrhythmias in Sweden (Unknown route)